

18 March 2026

ASX Announcement

Nasodine patent accepted in the Philippines

- Philippines is considered an important market for Nasodine and this patent adds to commercial protection for the Nasodine range in that market
- Patent covers the use of Nasodine Nasal Spray and other Nasodine products in relation to treating and reducing viral shedding associated with SARS-CoV-2 (COVID)

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that its patent titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes" has been accepted in the Philippines.

The patent protects the use of Nasodine Nasal Spray ("Nasodine") or any other intranasal povidone-iodine (PVP-I) preparations as a method of reducing the viral load of SARS-CoV-2 in the nose. Granted claims also cover pre-exposure prophylaxis (preventative use prior to exposure) against SARS-CoV-2.

"This patent is a commercially useful extension to our common cold patent in one of our most important markets, the Philippines," said Firebrick Executive Chairman, Dr Peter Molloy. "It covers the use of PVP-I in the nose or throat in relation to SARS-CoV-2 and therefore would protect a gargle or throat spray as well as the nasal spray for that purpose."

The Company is currently seeking regulatory approval in the Philippines and anticipates approval during 2026.

This patent, which expires in 2040, has also been accepted and/or granted in the United States, Europe, Australia, and multiple other countries.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and plans to expand sales to up to 10 markets over three years, including the Philippines. For further information, visit <https://nasodine-sg.com/>

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com